Torrent Pharmaceuticals has posted a robust 30 percent jump in its consolidated profit after tax (PAT) at Rs 591 crore for the September quarter, driven by strong sales across key markets. The Ahmedabad-based drugmaker had posted a PAT of Rs 453 crore in the same quarter last year. According to a regulatory filing, the company’s revenue for the second quarter rose to Rs 3,302 crore, compared to Rs 2,889 crore in the year-ago period. India revenues stood at Rs 1,820 crores were up by 12% led by outperformance in focus therapies. In India, Torrent Pharma’s largest market, revenues grew 12% to Rs 1,820 crore, driven by strong performance in its focus therapy areas. The company’s international operations also delivered healthy growth — revenues from Brazil rose 21% to Rs 318 crore, while the US business saw a 26% jump to Rs 337 crore. In Germany, revenues increased 5% to Rs 303 crore during the quarter. Torrent Pharma, with annual revenues of more than Rs 11,500 crores, is the flagship Company of the Torrent Group, with group revenues of ~Rs 45,000 crores. It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and has 8 manufacturing facilities, of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 750+ scientists.